Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2020-12-10
Target enrollment:
Participant gender:
Summary
This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body
Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer
(NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving
treatment with a targeted agent such as gefitinib, erlotinib and icotinib.
Phase:
Phase 2
Details
Lead Sponsor:
Tongji Hospital
Collaborators:
Hubei Cancer Hospital Renmin Hospital of Wuhan University Wuhan Union Hospital, China Wuhan University